medication-migraine-prevention-galcanezumab-monthly-loading-dose

Outcomes

01
pain-headache-migraine-menstrual-monthly-headache-days-change-from-baseline-count-self-reported
2 evidence rows
- igarashi-h_2023_rct_galcanezumab-effects-on-migraine-severity-and-symptoms-in-japanese-patients-with-episodic-migraine-secondary-analysis-of-a-phase-2-randomized-trial
- igarashi_2022_rct_galcanezumab-effects-on-migraine-severity-and-symptoms-in-japanese-patients-with-episodic-migraine
02
pain-headache-migraine-menstrual-monthly-headache-days-change-from-baseline-percent-self-reported
1 evidence row
- igarashi-h_2023_rct_galcanezumab-effects-on-migraine-severity-and-symptoms-in-japanese-patients-with-episodic-migraine-secondary-analysis-of-a-phase-2-randomized-trial
03
pain-headache-migraine-monthly-headache-days-change-from-baseline-count-self-reported
1 evidence row
- igarashi_2022_rct_galcanezumab-effects-on-migraine-severity-and-symptoms-in-japanese-patients-with-episodic-migraine
04
pain-headache-migraine-monthly-headache-days-with-aura-change-from-baseline-count-self-reported
2 evidence rows
- igarashi-h_2023_rct_galcanezumab-effects-on-migraine-severity-and-symptoms-in-japanese-patients-with-episodic-migraine-secondary-analysis-of-a-phase-2-randomized-trial
- igarashi_2022_rct_galcanezumab-effects-on-migraine-severity-and-symptoms-in-japanese-patients-with-episodic-migraine
05
pain-headache-migraine-monthly-headache-days-with-aura-count-self-reported
1 evidence row
- anonymous_2022_rct_galcanezumab-effects-on-migraine-severity-and-symptoms-in-japanese-patients-with-episodic-migraine-secondary-analysis-of-a-phase-2-randomized-trial
06
pain-headache-migraine-monthly-headache-days-with-nausea-vomiting-change-from-baseline-count-self-reported
2 evidence rows
- igarashi-h_2023_rct_galcanezumab-effects-on-migraine-severity-and-symptoms-in-japanese-patients-with-episodic-migraine-secondary-analysis-of-a-phase-2-randomized-trial
- igarashi_2022_rct_galcanezumab-effects-on-migraine-severity-and-symptoms-in-japanese-patients-with-episodic-migraine
07
pain-headache-migraine-monthly-headache-days-with-nausea-vomiting-count-self-reported
1 evidence row
- anonymous_2022_rct_galcanezumab-effects-on-migraine-severity-and-symptoms-in-japanese-patients-with-episodic-migraine-secondary-analysis-of-a-phase-2-randomized-trial
08
pain-headache-migraine-monthly-headache-days-with-photophobia-phonophobia-change-from-baseline-count-self-reported
2 evidence rows
- igarashi-h_2023_rct_galcanezumab-effects-on-migraine-severity-and-symptoms-in-japanese-patients-with-episodic-migraine-secondary-analysis-of-a-phase-2-randomized-trial
- igarashi_2022_rct_galcanezumab-effects-on-migraine-severity-and-symptoms-in-japanese-patients-with-episodic-migraine
09
pain-headache-migraine-monthly-headache-days-with-photophobia-phonophobia-count-self-reported
1 evidence row
- anonymous_2022_rct_galcanezumab-effects-on-migraine-severity-and-symptoms-in-japanese-patients-with-episodic-migraine-secondary-analysis-of-a-phase-2-randomized-trial
10
pain-headache-migraine-monthly-headache-days-with-prodromal-symptoms-change-from-baseline-count-self-reported
2 evidence rows
- igarashi-h_2023_rct_galcanezumab-effects-on-migraine-severity-and-symptoms-in-japanese-patients-with-episodic-migraine-secondary-analysis-of-a-phase-2-randomized-trial
- igarashi_2022_rct_galcanezumab-effects-on-migraine-severity-and-symptoms-in-japanese-patients-with-episodic-migraine
11
pain-headache-migraine-monthly-headache-days-with-prodromal-symptoms-count-self-reported
1 evidence row
- anonymous_2022_rct_galcanezumab-effects-on-migraine-severity-and-symptoms-in-japanese-patients-with-episodic-migraine-secondary-analysis-of-a-phase-2-randomized-trial
12
pain-headache-migraine-monthly-moderate-to-severe-headache-days-change-from-baseline-count-self-reported
2 evidence rows
- igarashi-h_2023_rct_galcanezumab-effects-on-migraine-severity-and-symptoms-in-japanese-patients-with-episodic-migraine-secondary-analysis-of-a-phase-2-randomized-trial
- igarashi_2022_rct_galcanezumab-effects-on-migraine-severity-and-symptoms-in-japanese-patients-with-episodic-migraine
13
pain-headache-migraine-monthly-moderate-to-severe-headache-days-count-self-reported
1 evidence row
- anonymous_2022_rct_galcanezumab-effects-on-migraine-severity-and-symptoms-in-japanese-patients-with-episodic-migraine-secondary-analysis-of-a-phase-2-randomized-trial
14
pain-headache-migraine-monthly-severe-headache-days-change-from-baseline-count-self-reported
2 evidence rows
- igarashi-h_2023_rct_galcanezumab-effects-on-migraine-severity-and-symptoms-in-japanese-patients-with-episodic-migraine-secondary-analysis-of-a-phase-2-randomized-trial
- igarashi_2022_rct_galcanezumab-effects-on-migraine-severity-and-symptoms-in-japanese-patients-with-episodic-migraine
15
pain-headache-migraine-monthly-severe-headache-days-nrs-7-to-10-count-self-reported
1 evidence row
- anonymous_2022_rct_galcanezumab-effects-on-migraine-severity-and-symptoms-in-japanese-patients-with-episodic-migraine-secondary-analysis-of-a-phase-2-randomized-trial
16
pain-headache-migraine-nausea-vomiting-monthly-headache-days-change-from-baseline-percent-self-reported
1 evidence row
- igarashi-h_2023_rct_galcanezumab-effects-on-migraine-severity-and-symptoms-in-japanese-patients-with-episodic-migraine-secondary-analysis-of-a-phase-2-randomized-trial
17
pain-headache-migraine-pain-severity-mean-nrs-self-reported
1 evidence row
- anonymous_2022_rct_galcanezumab-effects-on-migraine-severity-and-symptoms-in-japanese-patients-with-episodic-migraine-secondary-analysis-of-a-phase-2-randomized-trial
18
pain-headache-migraine-photophobia-phonophobia-monthly-headache-days-change-from-baseline-percent-self-reported
2 evidence rows
- igarashi-h_2023_rct_galcanezumab-effects-on-migraine-severity-and-symptoms-in-japanese-patients-with-episodic-migraine-secondary-analysis-of-a-phase-2-randomized-trial
- igarashi_2022_rct_galcanezumab-effects-on-migraine-severity-and-symptoms-in-japanese-patients-with-episodic-migraine
19
pain-headache-migraine-severity-3-point-scale-change-from-baseline-self-reported
1 evidence row
- igarashi-h_2023_rct_galcanezumab-effects-on-migraine-severity-and-symptoms-in-japanese-patients-with-episodic-migraine-secondary-analysis-of-a-phase-2-randomized-trial

medication-migraine-prevention-galcanezumab-monthly-loading-dose

Outcomes

pain-headache-migraine-menstrual-monthly-headache-days-change-from-baseline-count-self-reported

pain-headache-migraine-menstrual-monthly-headache-days-change-from-baseline-percent-self-reported

pain-headache-migraine-monthly-headache-days-change-from-baseline-count-self-reported

pain-headache-migraine-monthly-headache-days-with-aura-change-from-baseline-count-self-reported

pain-headache-migraine-monthly-headache-days-with-aura-count-self-reported

pain-headache-migraine-monthly-headache-days-with-nausea-vomiting-change-from-baseline-count-self-reported

pain-headache-migraine-monthly-headache-days-with-nausea-vomiting-count-self-reported

pain-headache-migraine-monthly-headache-days-with-photophobia-phonophobia-change-from-baseline-count-self-reported

pain-headache-migraine-monthly-headache-days-with-photophobia-phonophobia-count-self-reported

pain-headache-migraine-monthly-headache-days-with-prodromal-symptoms-change-from-baseline-count-self-reported

pain-headache-migraine-monthly-headache-days-with-prodromal-symptoms-count-self-reported

pain-headache-migraine-monthly-moderate-to-severe-headache-days-change-from-baseline-count-self-reported

pain-headache-migraine-monthly-moderate-to-severe-headache-days-count-self-reported

pain-headache-migraine-monthly-severe-headache-days-change-from-baseline-count-self-reported

pain-headache-migraine-monthly-severe-headache-days-nrs-7-to-10-count-self-reported

pain-headache-migraine-nausea-vomiting-monthly-headache-days-change-from-baseline-percent-self-reported

pain-headache-migraine-pain-severity-mean-nrs-self-reported

pain-headache-migraine-photophobia-phonophobia-monthly-headache-days-change-from-baseline-percent-self-reported

pain-headache-migraine-severity-3-point-scale-change-from-baseline-self-reported